CY1117501T1 - Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων - Google Patents

Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων

Info

Publication number
CY1117501T1
CY1117501T1 CY20161100404T CY161100404T CY1117501T1 CY 1117501 T1 CY1117501 T1 CY 1117501T1 CY 20161100404 T CY20161100404 T CY 20161100404T CY 161100404 T CY161100404 T CY 161100404T CY 1117501 T1 CY1117501 T1 CY 1117501T1
Authority
CY
Cyprus
Prior art keywords
antibodies
disease treatment
compound
treatment concerning
concerning
Prior art date
Application number
CY20161100404T
Other languages
English (en)
Inventor
Youe-Kong Shue
Farah Kondori Babakhani
Franklin W Okumu
Pamela Suzanne Sears
Starr Louise Miller-Shangle
Robert Brian Walsh
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1117501T1 publication Critical patent/CY1117501T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη θεραπευτική αγωγή ή την πρόληψη νοσημάτων σχετιζομένων με τη χρήση αντιβιοτικών ή χημειοθεραπειών καρκίνου ή αντιιικών θεραπειών, όπως κολίτιδα, ψευδομεμβρανώδης κολίτιδα, σχετιζόμενη με αντιβιοτικά διάρροια και μολύνσεις λόγω των ειδών C. Difficile, C. Perfringens, Staphylococcus, όπου συμπεριλαμβάνεται ο ανθεκτικός στην μεθικιλλίνη Staphylococcus aureus (MRSA) ή Enterococcus, όπου συμπεριλαμβάνονται οι ανθεκτικοί στην βανκομυκίνη εντερόκοκκοι (VRE) με την Ένωση I.
CY20161100404T 2004-05-14 2016-05-13 Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων CY1117501T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57069704P 2004-05-14 2004-05-14
EP09156339.5A EP2070530B1 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics

Publications (1)

Publication Number Publication Date
CY1117501T1 true CY1117501T1 (el) 2017-04-26

Family

ID=35428857

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100404T CY1117501T1 (el) 2004-05-14 2016-05-13 Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων
CY20191100248T CY1121284T1 (el) 2004-05-14 2019-02-28 Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100248T CY1121284T1 (el) 2004-05-14 2019-02-28 Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων

Country Status (17)

Country Link
US (2) US20070173462A1 (el)
EP (4) EP2305244B1 (el)
JP (2) JP5734545B2 (el)
AT (1) ATE516024T1 (el)
BR (1) BRPI0511119A (el)
CA (2) CA2776682A1 (el)
CY (2) CY1117501T1 (el)
DK (3) DK2305245T3 (el)
ES (4) ES2565609T3 (el)
HU (3) HUE031581T2 (el)
LT (1) LT2305245T (el)
MX (2) MX344601B (el)
PL (3) PL2305245T3 (el)
PT (2) PT2305244T (el)
SI (2) SI2305245T1 (el)
TR (1) TR201902533T4 (el)
WO (1) WO2005112990A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
BRPI0519890A2 (pt) * 2005-01-31 2009-03-31 Optimer Pharmaceuticals Inc macrociclos de 18 elementos e seus análogos
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
KR101399621B1 (ko) * 2005-10-21 2014-06-18 옵티머 파마슈티칼즈, 인코포레이티드 클로스트리듐 디피실리 관련 설사의 치료 방법
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
US20110008303A1 (en) * 2008-03-17 2011-01-13 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) * 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
JP2013510900A (ja) * 2009-11-17 2013-03-28 ピラマル・ライフ・サイエンシーズ・リミテッド 炎症性疾患治療のための大環状ラクトン誘導体の使用
EP2519108A4 (en) * 2009-12-31 2013-10-16 Ira Milton Trachtman COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF INFLAMMATORY INTESTINAL DISEASE
PE20130310A1 (es) * 2010-05-18 2013-04-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
EP3139932B1 (en) 2014-05-09 2018-08-01 Astellas Pharma Europe Ltd. Treatment regimen for tiacumicin compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4918174A (en) * 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
IN186245B (el) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
SI1527100T1 (sl) * 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
KR100972542B1 (ko) 2002-07-29 2010-07-28 옵티머 파마슈티칼즈, 인코포레이티드 티아쿠미신 제조법
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
SI2305245T1 (sl) 2019-04-30
JP6101010B2 (ja) 2017-03-22
PT2305245T (pt) 2019-03-19
CA2566687A1 (en) 2005-12-01
HUE027757T2 (en) 2016-11-28
JP5734545B2 (ja) 2015-06-17
MXPA06013245A (es) 2007-05-09
ES2565609T3 (es) 2016-04-05
EP2305245A1 (en) 2011-04-06
DK2305245T3 (en) 2019-03-25
ES2608046T3 (es) 2017-04-05
TR201902533T4 (tr) 2019-03-21
DK2070530T3 (da) 2016-05-17
ES2395404T3 (es) 2013-02-12
PL2305245T3 (pl) 2019-05-31
EP2070530A1 (en) 2009-06-17
US20070173462A1 (en) 2007-07-26
ATE516024T1 (de) 2011-07-15
WO2005112990A2 (en) 2005-12-01
EP1765312A2 (en) 2007-03-28
CA2776682A1 (en) 2005-12-01
EP2305245B1 (en) 2019-01-02
HUE031581T2 (en) 2017-07-28
DK2305244T3 (en) 2017-01-30
PL2305244T3 (pl) 2017-04-28
MX344601B (es) 2016-12-20
HUE043945T2 (hu) 2019-09-30
EP1765312B1 (en) 2011-07-13
JP2012197309A (ja) 2012-10-18
ES2713954T3 (es) 2019-05-24
PL2070530T3 (pl) 2016-06-30
CA2566687C (en) 2012-07-24
LT2305245T (lt) 2019-03-12
CY1121284T1 (el) 2020-05-29
BRPI0511119A (pt) 2007-11-27
PT2305244T (pt) 2016-12-29
EP1765312A4 (en) 2007-08-22
WO2005112990A3 (en) 2006-01-05
SI2070530T1 (sl) 2016-05-31
EP2305244B1 (en) 2016-10-12
EP2305244A1 (en) 2011-04-06
JP2007537290A (ja) 2007-12-20
US20130274175A1 (en) 2013-10-17
EP2070530B1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
CY1117501T1 (el) Αγωγη νοσηματων τα οποια σχετιζονται με τη χρηση αντιβιοτικων
CY1119601T1 (el) Προαγωγεις αποπτωσης
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
CY1111772T1 (el) Μονοϋδροχλωρικο μονοϋδρικο αλας 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλο)-5-τριφλουορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλο-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
CR9866A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicoticos y neurodegenerativos
AR050717A1 (es) Composiciones farmaceuticas
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EA201190095A1 (ru) Производные актагардина
BRPI0615614A2 (pt) compostos orgánicos
NO20074251L (no) Nye isotiazolokinoloner of relaterte forbindelser som anti-infektive midler
GT200500308A (es) Nonadepsipeptidos acilados ii
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
EA200870058A1 (ru) Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
GT200700105A (es) Inhibidor del factor xa
CY1108780T1 (el) Σατραπλατινη για την αντιμετωπιση ανθεκτικων ή επιμονων νεοπλασιων
UY38934A (es) Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
GT200600132A (es) Una oxindoloxazolidinona como agente antibacteriano
CL2007001629A1 (es) Compuestos derivados de oximilo macrociclico, inhibidores de proteasa de hepatitis c; composicion farmaceutica, util para el tratamiento de infeccion por hepatitis c.
UY31002A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona